AAPG
Ascentage Pharma Group International
15.40$
-3.4%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Ratios
Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||||||
| – | – | 87.0% | 93.4% | 97.0% | 97.0% | 97.0% | 95.9% | 90.9% | 86.6% | 83.7% | 82.8% | |
| – | – | -426.6% | -155.1% | -38.1% | -38.3% | -38.6% | -101.1% | -314.9% | -264.1% | -226.9% | -214.8% | |
| – | – | -444.4% | -164.2% | -39.9% | -40.4% | -41.3% | -103.5% | -321.4% | -268.5% | -230.4% | -223.0% | |
| – | – | -385.6% | -171.2% | -82.0% | -58.0% | -13.8% | 17.9% | 21.7% | -87.2% | -169.2% | -219.8% | |
| Returns | ||||||||||||
| – | – | -2,695.8% | -144.3% | -70.5% | -213.1% | -230.2% | -476.2% | -302.1% | -178.6% | -184.0% | -481.2% | |
| – | – | -65.1% | -35.6% | -17.4% | -21.5% | -23.2% | -48.1% | -66.0% | -59.7% | -61.5% | -82.6% | |
| Balance Sheet & Debt | ||||||||||||
| 83 | -477 | 713 | -371 | 588 | -482 | 411 | -458 | 55 | -506 | -1,248 | 185 | |
| 20.2% | 2.4% | 2.4% | 24.7% | 24.7% | 10.1% | 10.1% | 10.1% | 21.9% | 33.4% | 33.4% | 17.2% | |
| 2.8 | 10.2 | 29.5 | 1.0 | 2.2 | 2.9 | 6.2 | 2.9 | 2.6 | 1.5 | 0.9 | 3.7 | |
| Per Share | ||||||||||||
| – | – | -22.46 | -3.74 | -7.30 | -1.80 | -7.79 | -16.11 | -23.56 | -25.57 | -26.34 | -28.70 | |
| – | – | 5.05 | 2.28 | 18.30 | 4.46 | 18.84 | 15.57 | 7.33 | 9.52 | 11.43 | 12.87 | |
| 33.43 | 0.21 | 0.83 | 2.59 | 10.36 | 0.85 | 3.38 | 3.38 | 7.80 | 14.31 | 14.31 | 5.96 | |
| – | – | -19.49 | -3.90 | -15.01 | -2.59 | -2.61 | 2.78 | 1.59 | -8.30 | -19.35 | -28.28 | |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.